Skip to main content

Table 2 Estimated odds of serious infection for treatment strategies compared to placebo

From: Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis

Treatment strategy

Comparator

Odds ratio

Standard error

95% Confidence interval

Infliximab

Placebo

1.36

0.45

0.57

3.27

Adalimumab

Placebo

0.77

0.36

0.38

1.56

Certolizumab pegol

Placebo

2.37

0.50

0.88

6.38

Natalizumab

Placebo

0.80

0.40

0.37

1.73

Ustekinumab

Placebo

0.40

0.49

0.16

1.05

Vedolizumab

Placebo

0.75

0.38

0.36

1.58

Golimumab

Placebo

1.71

0.67

0.46

6.31

Methotrexate

Placebo

0.52

1.28

0.04

6.34

Azathioprine/6MP

Placebo

1.43

0.61

0.43

4.76

Prednisone

Placebo

1.92

0.85

0.36

10.21

Budesonide

Placebo

1.99

1.65

0.08

50.97

Aminosalicylate

Placebo

1.37

1.40

0.09

21.47

Antibiotic

Placebo

1.01

1.07

0.12

8.34

Tacrolimus

Placebo

1.19

2.02

0.02

62.32

Methotrexate + prednisone

Placebo

2.94

1.45

0.17

50.23

Azathioprine/6MP + prednisone

Placebo

2.37

1.76

0.07

75.25

Aminosalicylate + prednisone

Placebo

7.32

2.41

0.06

832.34

Budesonide + prednisone

Placebo

1.89

2.18

0.03

135.88

MMF + prednisone

Placebo

4.14

2.07

0.07

241.50

Infliximab + azathioprine/6MP

Placebo

1.10

0.65

0.31

3.97

Azathioprine/6MP + aminosalicylate

Placebo

1.35

2.11

0.02

83.66

Natalizumab + inflximab

Placebo

0.71

2.06

0.01

40.65

Infliximab + azathioprine/6MP + prednisone

Placebo

0.32

2.33

0.00

30.40

  1. Abbreviations: 6MP 6-mercaptopurine, MMF mycophenolate mofetil